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ABSTRACT 
 
 The term “diabesity” is a pandemic that is threatening populations 
worldwide and is the term is finding itself as a household name, fueling itself 
through the high-fat diet and sedentary lifestyle. As a result of these living 
choices, the population is suffering from lipotoxicity, the underlying cause of Type 
2 Diabetes Mellitus (T2DM) and insulin resistance. Lipolytic control resides 
around the rate-limiting enzyme, adipose triglyceride lipase, which is normally 
downregulated in the insulin-stimulated state. This is the signal that is aberrant in 
patients who have T2DM and could be a significant factor in lipotoxicity. This 
state of lipotoxicity leads to many complications, increasing the risk of heart 
disease, heart attack, blindness, nephropathy, neuropathy, and stroke. 
Vasculature damage also can lead to poor perfusion of the lower extremities, 
increasing the risk of ulcer, gangrene, and amputation of the foot. 
 An area of research delving into this issue lies within the mammalian 
target of rapamycin complex 1 (mTORC1), as it mediates the antilipolytic signal 
and decreases ATGL expression. This discovery was further clarified when the 
	   vi	  
Kandror lab identified the transcription factor early growth factor 1 (Egr1) as the 
protein that binds to the promoter region of ATGL and downregulates its 
transcription. Egr1 has also been thought to be a factor in the development of 
insulin resistance in the hyperinsulemic state.  
 To date, we have experimented upon murine 3T3-L1 and human 
adipocytes. We have developed a double transgenic mouse positive for reverse 
tetracycline transactivator (rtTA) and myc-tagged ras homolog enriched in brain 
(Rheb), which is a misnomer as it is located in adipose tissue (AT). With the 
mTORC1 axis hyperactive, we seek to show that Egr1 is a rich target in diabetes 
and lipotoxicity, regulating and inhibiting ATGL levels through mTORC1. 
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INTRODUCTION 
 
 
1. Obesity, Diabetes, and Public Health 
 
Today, two of the most common diseases afflicting the world’s population 
are Type 2 Diabetes Mellitus (T2DM) and Obesity, usually working in tandem [1]. 
The projected increase in global diabetes was measured to rise 3.5 fold in forty 
years, from one hundred million people in 1990 to three hundred and fifty million 
in 2030. Of course, this statistic does not consider those with impaired glucose 
tolerance, which is projected to include another three hundred and fifty million 
people [2]. Figure 1 displays the projected increase in diabetes globally, from 
2000 – 2030 [5]. Currently in the United States, Diabetes affects 8.3 percent of 
the nation’s population, for a total of 25.8 millions people – 7.0 million of which 
are undiagnosed based upon fasting glucose and hemoglobin A1c (A1c) levels 
[3]. Between 1980 and 2008, the number of people in the world living with 
diabetes increased 100 percent or doubled. Besides population growth, this rise 
in cases of diabetes can be attributed to a slower lifestyle and the Western diet 
[1]. As a result of the tandem efforts of T2DM and Obesity, the term “diabesity” is 
used often in the medical community [4].  
Obesity and it associated diseases have becomes an extremely prevalent 
problem in the United States. In the last thirty years, the amount of children 
diagnosed as obese has tripled and T2DM is more commonly diagnosed at a 
younger age. As a result, the tandem effect of diabetes and obesity, associated 
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with the term “adult-onset,” is now found in nearly half of the cases of pediatric 
diabetes. Of course, this does not consider 90-95% of all adult cases. Because of 
the many diseases associated with obesity, the term “metabolic syndrome” is 
now used to describe many of these disorders, such as high blood pressure, pro-
inflammatory state, insulin resistance, associated with T2DM and obesity [8]. 
For the body to properly function, the levels of glucose must be monitored 
rigorously. The concentration of blood glucose within metabolically normal people 
stay between 4 and 6 mM by maintaining balance of glucose uptake and release 
in the liver, skeletal muscle, and adipose tissue [9]. After a meal, the beta cells of 
the pancreatic islets of Langerhans release insulin, leading the intake of glucose 
in the skeletal muscle and adipose tissue [10]. This is the sequence of events 
during consumption, though during overconsumption, these mechanisms are not 
adequate to restore blood glucose levels to a normal level. As such, 
overconsumption will lead to hyperglycemia and further complications [11].  
Insulin resistance leads to the chronic state of hyperglycemia, but there 
are many others researched that are likely to work together with hyperglycemia. 
Other areas of interest in studying the pathological state of insulin 
unresponsiveness include aberrant signaling, defective glucose transporter type 
4 (GLUT4) translocation, and decreased secretion of insulin sensitizing 
adipokines. The level of cross-talk between these mechanisms is still unknown, 
though the complications of this pathological states have been studied 
thoroughly. 
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 Diabetes leads to many complications, beginning with damages to the 
vasculature. Of course, vasculature damages has many implications, increasing 
the risk of heart disease, heart attack, blindness, nephropathy, neuropathy, and 
stroke. Vasculature damage also can lead to poor perfusion of the lower 
extremities, increasing the risk of ulcer, gangrene, and amputation of the foot [6]. 
Currently in the United States, Diabetes is the seventh leading cause of death 
and has the second-largest increase in death rate between 2010 and 2011 (3.4 
percent) [7]. 
 
 
 
Figure 1. The projected increase in Diabetes from 2000 to 2030. Diabetes 
is projected to increase over 380 million people worldwide. In light blue, is the 
amount of people diagnosed with diabetes in a certain region, and in dark 
blue is the projected increase in 2030. Below the bars is the percentage 
increase reflected by the projections [5]. 
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2. Type 1 Diabetes Mellitus (T1DM) v. Type 2 Diabetes Mellitus (T2DM)  
 
 
Diabetes Mellitus is a disease where your blood glucose or blood sugar 
levels are high. This disease was observed by Joseph von Mering and Oskar 
Minkowski in the late 1880s, when they noticed the sweet urine of dogs with 
excised pancreases, leading Minkowski to believe that the pancreas secretes an 
integral substance in glucose regulation [7]. Blood glucose is regulated by the 
hormone insulin, secreted by the beta cells in the islets of Langerhans located in 
the pancreas. This was reported by Sir Edward Albert Sharpey-Schafer, when he 
observed that diabetes was the result of a lack of insulin. Furthermore, he coined 
the term insulin from the Latin “insula,” meaning island. The word island was 
chosen, as this disease is a result of dysfunctional islets of Langerhans. 
Therefore, there are two ways in which glucose regulation can be impaired – lack 
of insulin secretion by the pancreas or lack of response to the insulin secreted by 
the pancreas. The term “Diabetes Mellitus,” literally means to pass sweet urine 
and was known in the seventeenth century as “pissing evil.” In a 1992 Science 
article, Dr. John Mcgarry questions if the direction of Diabetes research would 
have been different had von Mering and Minkowski smelled acetone in the breath 
before tasting sugar in the urine. He then continues to argue that acetone, a by-
product of ketoacids, may have a larger role in the pathogenesis of insulin 
resistance and diabetes [7]. Our lab focuses on lipid metabolism and its relation 
and role in Diabetes Mellitus. 
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 T1DM is a case of impaired glucose tolerance at the level of the pancreas. 
T1DM is characterized by the inability of the body to produce insulin as a result of 
an autoimmune destruction of the pancreatic beta cells. This disease often 
occurs during childhood and patients become dependent upon insulin injections 
for the rest of their lives. The classic symptoms of a T1DM patient include 
polyuria, polydipsia, polyphagia, unexplained weight loss, fatigue, nausea, and 
blurred vision. Diagnostics measures include a fasting plasma glucose (FPG) 
level greater than or equal to 126 milligrams per deciliter, a 2-hour plasma 
glucose level greater than 200 mg/dL during a 75-g oral glucose tolerance test 
(OGTT), or random plasma glucose greater than or equal to 200 mg/dL in a 
patient with classics symptoms of hyperglycemia.  
 On the other hand, T2DM, also referred to as non insulin-dependent 
diabetes mellitus (NIDDM), is a case of impaired glucose tolerance as it is 
resistant to insulin. Other associated characteristics of T2DM include inadequate 
insulin secretion and excessive or inappropriate glucagon secretion. The classic 
symptoms of T2DM include polyuria, polydipsia, polyphagia, weight loss, blurred 
vision, lower-extremity paresthesias, and yeast infections. Diagnostics measures 
include a fasting plasma glucose (FPG) level greater than or equal to 126 
milligrams per deciliter, a 2-hour plasma glucose level greater than 200 mg/dL 
during a 75-g oral glucose tolerance test (OGTT), or random plasma glucose 
greater than or equal to 200 mg/dL in a patient with classics symptoms of 
hyperglycemia. In addition to being known as NIDDM, T2DM is also known to be 
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associated with the term “adult onset,” and is strongly associated with obesity. As 
the average onset has been lowered to middle adulthood, other classic 
symptoms are screened at this age. These include a sustained blood pressure 
over 135/80 mm Hg and overweight associated with one or more risk factors for 
diabetes. These risk factors include a blood pressure above 140/90 mm Hg, HDL 
levels below 35 mg/dL, or triglyceride levels above 250 mg/dL. Today, T1DM 
accounts for just 5% of all cases of diabetes, with T2DM accounting for 95% of 
cases [6].  
 Currently, lipid metabolism defects is understood as the primary cause of 
insulin resistance [12]. In 1994, Unger and McGarry thought that it was increased 
plasma free fatty acids (FFA) increased the secretion of insulin, and this was the 
cause of insulin resistance in the periphery before diagnosis of diabetes [13]. The 
condition of elevated FFA is a condition known as “lipotoxicity,” which is the 
accumulation of FFA in the pancreatic beta-cell, skeletal muscle, and liver [14]. 
This research was furthered by Dresner et al., who showed that a rise in FFA led 
to insulin resistance by reducing the parallel signaling effects in the 
phosphatidylinositol 3-kinase (PI3K) pathway [15]. Metabolic dysfunction may be 
caused by accumulation of triacyglycerol (TAG) caused by an increased caloric 
intake above the TAG storage capacity of adipose tissue (AT) [16].   
 The disruption of PI3K pathway signaling leads to poor regulation of 
plasma FFA concentrations. The result of this abnormal metabolic function leads 
to elvated plasma FFA levels and contribute to “Metabolic Syndrome,” or high 
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cholesterol, high lipids, ectopic adiposity, hyperglycemia, and insulin resistance 
[17]. In short, high FFA will decrease insulin section by pancreatic beta-cells [18], 
decrease skeletal muscle uptake of glucose [19], alter gluconeogenesis 
suppression in states of high glucose [19], and lower the suppression of lipolysis 
in adipose tissue [20].  
 
3.  Lipolysis 
 
Triglycerides are hydrolyzed in a sequential process by three enzymes. 
These enzymes are Adipose Triglyceride Lipase (ATGL), Hormone Sensitive 
Lipase (HSL), and Monoglyceride Lipase (MGL) and they act to hydrolyze TGs in 
FFA and glycerol as expressed in Figure 2 in a process called lipolysis [27]. The 
proteins ATGL, HSL, and MGL, are all associated with the lipid bilayer. This 
process is tightly regulated in conditions of negative and positive energy balance. 
During times of negative energy balance such as fasting or physical exercise, the 
body experiences a large increase in FFA to provide energy via lipolysis. The 
FFA during this state is taken up by the liver and muscle to be used for beta-
oxidation in the mitochondria and specifically in the liver, ketogenesis.  On the 
other hand, during positive energy balance or the fed state, lipolysis is 
suppressed, and uptake of glucose occurs in the muscle, liver, and AT. 
Increaded plasma FFA in diabetes and obesity is caused by many factors, but 
defects of lipolysis in AT is key [21]. During insulin resistance, the body is unable 
to prevent the action of lipolysis, leading to severe metabolic consequences [22]. 
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Lipolysis is positively signaled by either catecholamines or natriuretic peptides 
and negatively signaled by insulin and catecholamines, as shown in Figure 3 
below [23]. 
 
 
Figure 2. The location and regulation of lipolysis proteins. Adipose 
triglyceride lipase, hormone sensitive lipase, and monoglyceride lipase are three 
enzymes active in the process of lipolysis, and this sequence of events is tightly 
regulated. This sequence of events depends on signaling from outside the cell, 
resulting in the phosphorylation of perilipin (PLIN1a). Phosphorylated PLIN1a in 
concert with fatty acid binding protein 4 (FABP4), works with a phosphorylated 
HSL to lyse diacylglycerol (DAG) to monoacylglycerol (MAG). Finally, 
monoglyceride lipase, will cleave MAG into glycerol and FFA (Figure taken from 
A. Girousse and D. Langin, 2012). 
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Figure 3. The lipolytic pathways in human adipocytes. Distinguished by color, 
the signal transduction pathways for catecholamines, natriuretic peptides, and 
insulin are expressed. Beta and alpha-2 receptors are used for catecholamines 
such as epinephrine and norepinephrine, type A receptor for atrial natriuretic 
peptide, and insulin receptor for insulin (Figure taken from Lafontan, M, 2008).  
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3.1 Enzymes and Co-Regulators 
 
 
 As mentioned previously, lipolysis involves the sequential actions of 
ATGL, HSL, and MGL. A study by Schweiger et al. used ATGL-knockout mice to 
show that the absence of this enzyme decreased the response of adipocyte 
lipolysis stimulated by catecholamines. The study continued to differentiate 
between ATGL and HSL – when just ATGL was knocked out, the study revealed 
a 70% decrease in lipolysis, however, when a specific HSL inhibitor was added 
to these ATGL-knockout mice, rate of lipolysis was decreased by 95% [24]. In 
2006, Kershaw et al. reconfirmed that lipolytic activity is increased in mice that 
overexpressed ATGL, however, this does not occur in mice that overexpress 
HSL, suggesting that ATGL is the rate-limiting enzyme in lipolysis [25-26].  
 
A. Adipose Triglyceride Lipase 
 Simultaneously discovered by three scientists in 2004, ATGL, was initially 
given three different names – adipose triglyceride lipase [28], phospholipase A2ξ 
[29], and desnutrin [30]. Despite the variety in name, scientists have pinned 
ATGL as the rate-limiting enzyme in lipolysis and that it is highly expressed in 
white adipose tissue (WAT) and brown adipose tissue (BAT) [25].  
 Studies of mouse ATGL have shown that the N-terminal contains the 
catalytic portion of the enzyme and that the C-terminal portion has a role in 
enzymatic regulation and interactions with the lipid droplet [36-37]. The regulation 
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is believed to be modulated by phosphorylation of two serine residues, Ser404 
and Ser428, on this C-terminal end [37]. Recently studying the mouse model, it 
was found that Ser406 was phosphorylated with exercise, fasting, and 
stimulation of the cyclic adenosine monophosphate (cAMP)-dependent pathway 
in protein kinase A (PKA)-dependent manner, which suggests that PKA has a 
role in ATGL regulation via phosphorylation [38]. Still, the modulator of Ser430 
phosphorylation is unknown.  
 In terms of transcriptional control, ATGL has been noted to contain a 
Peroxisome Proliferator-Activated Receptor-γ (PPARγ) in the promoter sequence 
of the mouse, resulting in an increase in ATGL expression upon addition of 
PPARγ-agonists, including substances in the family of thiazolidinediones [31]. As 
we would expect, during fasting, ATGL is upregulated to provide the body with 
energy via FFA, and during the fed-state, ATGL is down regulated through an 
insulin-mediated pathway [32]. In addition to these mechanisms, ATGL is also 
upregulated by SIRT1-mediated activation of the transcription factor Forkhead 
box protein O1 (FoxO1) [33]. Finally, scientists have also found a mild 
relationship between ATGL mRNA and protein levels, indicating that ATGL is 
regulated post-transcriptionally. Table 1 shows the factors that affect ATGL 
mRNA levels [39]. 
 Studies researching knockout ATGL mice show an increased level of 
adiposity, which leads to premature death as a result of cardiac steatosis and 
dysfunction [40]. Not only do these mice experience cardiac defects, but they are 
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unable to use FFA in BAT for thermogenesis, which prevents them from 
regulating their body temperature in the cold. These mice also experience 
increased insulin sensitivity due to a decreased plasma FFA. Lastly, despite 
weight gain during HFD, the mice are protected against induced insulin 
resistance and glucose intolerance [41]. On the other hand, mice that are 
overexpressing ATGL are much leaner as they avoid TAG accumulation in their 
adipocytes. Instead of a high plasma FFA as expected, these mice cope with a 
high FFA content by up-regulating mitochrondrial beta-oxidation, peroxisomal 
alpha-oxidation, and thermogenesis, which results in a higher body temperature 
and a much high concentration uncoupling protein 1 (UCP1) [42]. Finally, these 
mice exhibit an increase in insulin sensitivity in comparison with the wild-type 
(WT), leading to the conclusion that FFA concentration is not the only factor in 
insulin sensitivity. 
Table 1. Factors that effect ATGL mRNA levels and activity. ATGL is a 
heavily modulated enzyme, in terms of mRNA levels and activity. In states a 
positive energy balance, the body does not need FFA and downregulates ATGL 
mRNA levels. This includes insulin and mTOR, as well as isoproterenol. On the 
other hand, in states of negative energy balance, the body needs FFA for energy 
and upregulates ATGL mRNA, including stimulation by catecholamines, 
dexamethasone, thiazolidinediones, and FoxO1. Table taken from Lass et al. 
2011. 
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 a. Post-Translational Regulation of ATGL 
 
 In diabetes and obesity, ATGL regulation is important to researchers 
because of its role as the rate-limiting enzyme in AT lipolysis. ATGL is inhibited 
by interaction with a G0S2 protein (mentioned in Table 1), which is expressed at 
high levels in AT and liver [43]. As expected, a knockdown of this protein 
increases lipolysis and conversely, upregulation of this protein decreases 
lipolysis [44]. Another factor that modulates ATGL activity is CGI58, which 
activates ATGL. Like G0S2 and also mentioned in table 1, CGI58 directly 
interacts with ATGL, and is required for full ATGL activity. Chanarin-Dorfan 
Syndrome is caused by a mutation in CGI58 and leads to excessive TAG buildup 
in many tissues [45]. Another area of research in terms of post-translational 
regulation of ATGL is the insulin-stimulated breakdown of ATGL by selective 
autophagy or ubiquitination. In this scenario, insulin activates insulin receptor 
substrate 1 (IRS1), which in turn, binds the Src homology 2 (SH2) domain of p62, 
a protein involved in facilitating the interaction between ubiquitination proteins 
and autolysosomal proteins [46]. Lastly, research in our lab suggests ATGL 
interaction with an E3 ubiquitin ligase called parkin, when stimulated by insulin. 
Yet still, the exact mechanism for ATGL degradation is still unknown.  
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 b. Transcriptional Regulation of ATGL 
 
 The ATGL promoter is bound to and activated by three identified 
transcriptional factors: Interferon regulatory factor 4 (IRF4), FoxO1, PPARγ. In 
situations where insulin is high, ATGL levels drop because of signaling through 
FoxO1 that inhibits IRF4. Therefore, insulin is an inhibitor of an activator of ATGL 
[42]. As mentioned previously, the promoter region contains two FoxO1 binding 
sites, and Chakrabarti et al. show that co-transfection of luciferase and FoxO1 
with the ATGL promoter leads to expression of luciferase [43]. Conversely, a 
knockdown study of FoxO1 shows that basal lipolysis is diminished as a result of 
lower ATGL quantities. Insulin also serves to inhibit FoxO1, by activating Akt 
phosphorylation of FoxO1, and henceforth, diminishing its promotion of ATGL. 
Lastly, PPARγ also binds in the promoter region, transactivating the ATGL gene 
[44]. The ligands of PPARγ include acyl-CoAs, glycerol phospholipids, fatty acids, 
and eicosanoids [43]. This effect is enhanced by administration of 
thiazolidinediones, as noted in table 1, which are anti-diabetic drugs. This acts to 
activate PPARγ, leading to increased transcription of ATGL and increasing levels 
of FFA in the plasma [45].  
 On the other hand, early growth factor 1 (Egr1) is an inhibitory factor of 
ATGL by binding to the promoter region of ATGL and diminishing its expression. 
Insulin activated mammalian target of rapamycin complex 1 (mTORC1) 
increases expression of Egr1, and thus leads to a lower level of ATGL. A 
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simplified representation of this signaling pathway is shown in Figure 4. This data 
published by Chakrabarti et al. was shown with WT mouse embryonic fibroblasts 
(MEFs) and tuberous sclerosis type 2 (TSC2)-null MEFs that were transfected 
with luciferase cDNA linked to the ATGL promoter. In the TSC-2 null MEFs, 
mTORC1 was uninhibited and hyperactivated, leading to decreased luciferase 
expression. As expected, when treating with rapamycin, inhibitor of mTORC1, 
ATGL mRNA was found to be significantly increased. Chakrabarti et al. 
performed a time course study focusing upon ATGL and Egr1 levels in 3T3-L1 
adipocytes after treatment with insulin (Figure 5). The study shows that Egr1 
induction occurs with ATGL suppression after being fed with insulin. This data 
was confirmed with Chromatin immunoprecipitation (ChIP), which shows that 
Egr1 protein binds to the ATGL promoter region.  
 
Figure 4.  Regulation of Lypolysis. Lypolysis is highly regulated by insulin, 
which modulates through activation of mTORC1 and inhibition of FoxO1. 
mTORC1 – mammalian target of rapamycin complex 1 FoxO1 – forkhead box 
protein O1 ATGL – adipose triglyceride lipase 
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Figure 5. Insulin time course monitoring ATGL and Egr1 expression. 3T3-L1 
adipocytes were treated with 100 nM of insulin and mRNA levels of ATGL and 
Egr1 were measured with RT-qPCR and normalized to ribosomal protein 36B4. 
Western blot was used to measure levels of ATGL and Egr1, using acting as the 
loading control. Figure taken from Chakrabarti et al.  
  
 
B. Hormone Sensitive Lipase 
 
 In the early 1960’s, HSL was discovered and identified as a lipolytic 
enzyme-induced by fasting, adrenaline, or Adrenocorticotropic hormone (ACTH), 
and inhibited by insulin [50]. HSL is made from a single gene, though this single 
sequence has many transcriptional factors that cause variance and attribute to 
alternate isoforms. The most prevalent isoform in human adipose tissue, 
specifically WAT and BAT, is 88 kD and composed of 786 amino acids [51]. For 
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the best use of HSL, the protein requires the formation of a complex with FABP4, 
which transfers the FFA generated by the enzyme out of the cell, shown in Figure 
6 [52]. This was confirmed by Coe et al. in 1999, when they researched upon 
FABP knockout mice. This experiment showed that FFA levels in the plasma 
were decreased because FABP4 could not efficiently transfer FFA out of the 
adipocytes. As expected, intracellular FFA levels were increased as well as 
lipolytic capacity [53]. There are at least three sites of phosphorylation in human 
HSL: Ser552, Ser649, and Ser650, which are phosphorylated by either PKA or 
protein kinase G (PKG) [54]. This process is shown below in Figure 7 [55]. The 
latter two serines are thought to control the intrinsic activity of the enzyme, 
whereas the first site of phosphorylation promotes translocation of HSL from the 
cytosol to the LDs [56]. Another serine located on the human, Ser554, can be 
phosphorylated by Adenosine monophosphate-activated Protein Kinase (AMPK) 
and inhibits activation of the enzyme. The role of this phosphorylation site is likely 
to inhibit the nearby phosphorylation of Ser552 [56].  
 The use of HSL knockout mice was used to analyze the role of HSL. This 
study showed the accumulation of DG in skeletal muscle, adipose tissue, testis, 
and cardiac muscle [60]. In spite of this accumulation of DG, these mice did not 
have severe lipid accumulation unlike ATGL knockout mice, although they did 
show enlargement of some vital organs such as the heart, pancreas, liver, and 
spleen [61]. On the other hand, similar to ATGL knockout mice, the HSL 
knockout mice showed an increased and enlarged BAT, but still maintain the 
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ability to respond to cold temperatures, maintaining their thermogenetic function 
[62]. 
 Studies on HSL deficient models have been carried out, though results 
have varied. For example, HSL levels during obesity in subcutaneous adipose 
tissue have been reported above [57], below [58], and at normal levels [59], 
though the bulk of studies have shown that HSL is below normal levels. Thus far, 
HSL knockout studies have shown rather mild phenotypes, resulting in the 
conclusion that this enzyme is not associated with severe metabolic defects in 
humans.  
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Figure 6. The role of fatty acid binding protein in the function of hormone 
sensitive lipase. Hormone sensitive lipase proves to require fatty acid binding 
protein for efficient free fatty acid translocation. If this protein is not prevalent, 
FFA translocation would not be as efficient and intracellular FFA levels would be 
increased. HSL – hormone sensitive lipase FABP4 – fatty acid binding protein 
PKA – protein kinase A Ser – serine DG – diacylglycerol MG – monoacyglycerol 
Figure taken from Furuhashi and Hotamisligil 2008. 
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Figure 7. Hormone sensitive lipase signaling. Through the use of a G-protein 
coupled receptor (GPCR), epinephrine or glucagon is able to activate adenylate 
cyclase via a Gs protein. Adenylate cyclase then activates cAMP to activate PKA 
in the cascade, and phosphorylating HSL. HSL is then able to function properly 
on DG and further converting them to FFA and MG. cAMP – cyclic adenosine 
monophosphate PKA – protein kinase A ATP – adenosine triphosphase ADP – 
adenosine diphosphate HSL – hormone sensitive lipase ATGL – adipose 
triglyceride lipase MGL – monoglyceride lipase Figure taken from King et al. 
1996.  
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 C. Monoglyceride Lipase 
 
  
 As previously mentioned, monoglyceride lipase is responsible for cleaving 
monoglycerides to glycerol and FFA. MGL is specific to just monoglyceride and 
has no specificity for TG or DG [63]. Three years ago, Taschler et al. developed 
the first MGL knockout mice and showed that they accumulate MG in WAT, 
brain, and liver [64]. This enzyme, MGL, is thought to be constitutively active.   
 
4. Insulin-PI3K-Akt-TSC2-mTOR Axis 
 Insulin is the central hormone in diabetes and obesity and is known to be 
highly involved in activating the mammalian target of rapamycin complex 1 
(mTORC1) pathway. This protein complex, mTORC1, is involved in metabolic, 
protein synthesis, lipid synthesis, lysosome autophagy, lysosome biogenesis, cell 
cycle, and macromolecule biosynthetic pathways as shown in Figure 8 below 
[65]. In this pathway, insulin first binds to the insulin receptor (IR), which is a 
receptor tyrosine kinase (RTK), leading to autophosphorylation of IR on tyrosine 
residues after dimerization of the receptor. IR recruits and phosphorylates IRS1 
on specific tyrosine resiudes. IR and IRS recruit PI3K and Grb2 to the cell 
membrane. An activated Grb2 will activate the MAPK pathway [66]. On the other 
hand, an activated PI3K converts PIP2 to PIP3. PIP3 is then able to bind Akt and 
phosphoinositide-dependent kinase 1 (PDK1). This will allow for phosphorylation 
and activation of Akt [67]. Both ERK and Akt inhibits TSC2 by phosphorylating 
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many residues and suppressing the GTPase-activating protein (GAP) portion of 
TSC2. This GAP factor hydrolyzes GTP bound Ras homolog enriched in brain 
(Rheb), to GDP bound Rheb, inhibiting its actions. GTP bound Rheb is an 
activator of mTORC1, thus, Akt works to inhibit an inhibitor of Rheb, and in short, 
when Rheb is active via insulin signaling, activates mTORC1.  
 
 
 
Figure 8. mTORC1 – the activators, inhibitors, and actions. When activated 
by growth factors, such as insulin, IRS, which is an RTK, is able to activate 
mTORC1 through the AMPK pathway. As a result, an activated mTORC1 leads 
to protein synthesis, lipid synthesis, energy metabolism, and reduced lysosome 
biogenesis and autophagy. Figure taken from Laplante and Sabatini 2012. 
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 Within the pathway, is a negative feedback pathway residing around IRS1. 
Ribosomal protein, S6 kinase 1 (S6K1), phosphorylates IRS1 at several 
domains, reducing its affinity for IR and thus, decreasing PI3K activation and the 
overall signal [67]. This mechanism of overactive mTORC1 is hypothesized to be 
secondary to hyperinsulemia and decreases PI3K-Akt signaling through S6K1-
IRS1 mechanism, contributing to insulin resistance. As mentioned by this paper, 
Egr1 is an inhibitor of ATGL expression, and thus, an inhibitor of lipolysis, leading 
to larger levels of intracellular TAG. This was proved when an inhibitor of 
mTORC1, rapamycin, was used to inhibit this complex. As a result, inactive 
mTORC1 led to higher levels of ATGL and an increased rate of lipolysis. 
Conversely, in a similar experiment with TSC2-null mouse embryonic fibroblasts 
(MEFs), the result was overactive mTORC1 and larger levels of Egr1, an inhibitor 
of ATGL and thus, lower levels of lipolysis [69].  
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5. Thesis Objective 
 
 Despite the extensive research around the term “diabesity,” scientists 
believe that research in this area is still young. In the past two decades, 
researchers have shown that diabetes is not primarily a carbohydrate metabolism 
disease, but also that lipid metabolism plays a large role in the development and 
outcome of the disease. Now, insulin resistance is shown to develop through a 
dysregulation of lipid metabolism, which leads to glucose intolerance. The 
Kandror lab delves into this dysregulated lipid metabolic side of T2DM and 
obesity. 
In response to a recent discovery by Chakrabarti et al. demonstrating that 
Egr1 is responsible for the inhibition of ATGL through binding to its promoter 
region, this research project uses this discovery to guide the project in two 
directions. First, we are searching for the mechanism by which ATGL is 
degraded. The two culprits being researched here are Parkin and p62. The lab 
has validated that Egr1 plays a role in downregulating ATGL, but these two 
proteins involved in autophagy may be involved in actual ATGL degradation. 
Secondly, this project seeks to further research ATGL and mTORC1 
regulation through in vivo studies. By developing a double transgenic mouse line 
where myc-tagged Rheb can be induced in AT by doxycycline, we will be able to 
research states where ATGL is downregulated. This research will move in a 
direction researching these mice in a HFD state and measuring changes in TAG 
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levels. This could suggest a mechanism that will prevent insulin resistance by 
avoiding lipotoxicity.  
 
 
MATERIALS AND METHODS 
 
 
DNA Extraction and Genotyping  
 Obtain the last 2 mm of the tail of the mouse and place it directly into 75 ul 
alkaline lyse reagent in an eppendorf tube. Add 600 ul of Tail lysis buffer and 6 ul 
of Proteinase K. Stir at 800 rpm overnight at 37o C. Centrifuge at 14000g for 15 
minutes and then remove supernatant and place into a new eppendorf tube 
leaving mouse hair behind. Add 180 ul of isopropanol and mix with vortex and 
centrifuge for 15 minutes at 14,000g and collect top aqueous phase. Add 600 ul 
of chloroform, vortex and centrifuge for 10 minutes at 14,000g. Again, collect top 
aqueous phase into new eppendorf tube and add 600 ul of cold ethanol. Vortex 
and centrifuge for 5 minutes at 14,000g. White pellet will be visible at bottom of 
eppendorf tube. Remove supernatant and allow pellet to dry. Add 200 ul of 
ddH2O to dissolve DNA and prepare PCR mixture. For reaction mixture, use 1 ul 
of template DNA, 7.5 ul of H2O, 0.5 ul of forward and reverse primer for human-
myc-Rheb and reverse tetracycline transactivator (rtTA), and 12.5 ul of SYBR 
Green Master Mix. Primer sequences are as follows located in table 2 below. 
Use 6 ul of DNA and 30 ul of ethidium bromide loading buffer and load 20 ul into 
the gel. 
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Table 2. Primers used for genotyping mice.  
 
 
 
3T3-L1 Adipocyte Differentiation 
 Cell were incubated at 37o C and 10% CO2. The murine 3T3-L1 
preadipocytes were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
with 4.5 g/L glucose, L-glutamine, and sodium pyruvate (Cellgro 10-013-CV) and 
were supplemented with 10% donor bovine serum (Atlanta Biologicals S11350) 
and 1% penicillin-streptomycine-L-glutamine (Cellgro 30-009-Cl). This media was 
replaced every 2-3 days. 
 Two days post confluency, the cell media was replaced with an MDI 
induction media. This media consisted of DMEM with 4.5 g/L glucose, sodium 
pyruvate, and L-glutamine, supplemented with 10% fetal bovine serum (Gibco 
10437-028), 0.5 mM 3-isobutyl-1-methylxanthine (Sigma l-1078), 1 uM 
dexamethasone (Sigma D-4902), and 0.17 uM insulin (Sigma I-5500). The media 
was replaced every 2 days with a maintanence media. These cells were 
incubated at 37o C and 10% CO2. 
  
 
Primer Forward (5’ – 3’) Reverse (5’ – 3’) 
Human-myc-
Rheb 
CTATCGGCATGTGGGAAA
GT 
ATATTCATCCTGCCCTGC
TG 
rtTA CGCAATGGAGCAAAAGTAC
A 
AGGGCATCGGTAAACAT
CTG 
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Insulin Stimulation 
 Murine 3T3-L1 adipocytes stimulated with 100 nM insulin from bovine 
pancreas (Sigma I-5500), molecular weight 5733 g/mol. To create a 170 uM or 1 
mg/ml concentration, the insulin powder was dissolved in 0.02 M HCl. Prior to 
adding insulin, the cells were serum starved for 3 hours. 3 uL of the insulin stock 
solution was added in order to stimulate adipocytes with 100 nM of insulin. 
 
RNA Extraction After Stimulation of Adipocytes 
 RNA was extracted from 3T3-L1 adipocytes or murine adipocytes after 
treated or not treated with insulin or doxycycline. Addition of 1 mL of TRIzol 
reagent (Invitrogen 15596-026) was carried out to collect cell lysate, followed by 
addition of 20% chloroform to create a strawberry milk mixture after vigorous 
shaking. Mixture centrifuged at 14,000g for 15 min and then the top phase 
containing nucleic acids collected, and 2 volumes of isopropylalcohol added. 
Again, solutions vigorously shake and centrifuged at 14,000g for 10 minutes, 
showing a white pellet at the bottom of the eppendorf tube. Supernatant 
discarded and nucleic acids washed with 75% ethanol, vortexed, centrifuged at 
9,000 g for 10 minutes, and air-dried for 15 minutes. Pellet dissolved in 20 ul of 
RNase-free water (distilled and autoclaved with 0.1% diethylpyrocarbonate). 
RNA concentration measured using NanoDrop 1000 Spectrophotometer. 
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 To eliminate DNA, RNA samples treated with DNase. To each 10 ug 
sample of RNA, 10 ul of 10X DNase buffer (Invitrogen AM8170G) and 5 ul 
DNase 1 (Invitrogen AM2224) was added, and then samples were brought to a 
volume of 100 ul with RNase-free water. Samples incubated at 37o C for 45 
minutes. After incubation, add 300 ul of phenol and 200 ul of RNase-free water, 
vortex and centrifuge. Solution separates into two layers and upper aqueous 
layer collected. To this sample, 625 ul ethanol and 25 ul sodium acetate added. 
Samples then stored at -20o C overnight. Again, samples centrifuged at 12,000g 
for 15 minutes and supernatant removed, leaving white pellet at bottom of 
eppendorf tube. Pellet washed with 75% ethanol, vortexed, centrifuged, and air-
dried for 10 minutes. Then the RNA-pellet is dissolved in 20 ul of RNase free 
water and concentration measured using a NanoDrop 1000 spectrophotometer. 
 
RNA Extraction After Dissection of Mice 
 During dissection of AT depots, AT was washed in a plate of PBS and 
then weighed. After weight was recorded, AT depots was split into three sections 
and placed in three eppendorf tubes that were immediately placed in liquid 
nitrogen. After Post retrieval of subcutaneous, epididymal, and mesenteric 
adipose tissue depots, place AT in a tube on dry ice. Add 1 mL of TRIzol to 
frozen tissue, making sure that tissue has not thawed prior to addition of TRIzol. 
Using a polytron or mixer mill, homogenize tissue until mixture is smooth. 
Centrifuge sample at 5,000g for 15 minutes at room temperature. Collect the 
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middle phase and add 20% chloroform to create a strawberry milk mixture after 
vigorous shaking. Mixture centrifuged at 14,000g for 15 min and then the top 
phase containing nucleic acids collected, and 2 volumes of isopropylalcohol 
added. Again, solutions vigorously shake and centrifuged at 14,000g for 10 
minutes, showing a white pellet at the bottom of the eppendorf tube. Supernatant 
discarded and nucleic acids washed with 75% ethanol, vortexed, centrifuged at 
9,000 g for 10 minutes, and air-dried for 15 minutes. Pellet dissolved in 20 ul of 
RNase-free water (distilled and autoclaved with 0.1% diethylpyrocarbonate). 
RNA concentration measured using NanoDrop 1000 Spectrophotometer. 
 To eliminate DNA, RNA samples treated with DNase. To each 10 ug 
sample of RNA, 10 ul of 10X DNase buffer (Invitrogen AM8170G) and 5 ul 
DNase 1 (Invitrogen AM2224) was added, and then samples were brought to a 
volume of 100 ul with RNase-free water. Samples incubated at 37o C for 45 
minutes. After incubation, add 300 ul of phenol and 200 ul of RNase-free water, 
vortex and centrifuge. Solution separates into two layers and upper aqueous 
layer collected. To this sample, 625 ul ethanol and 25 ul sodium acetate added. 
Samples then stored at -20o C overnight. Again, samples centrifuged at 12,000g 
for 15 minutes and supernatant removed, leaving white pellet at bottom of 
eppendorf tube. Pellet washed with 75% ethanol, vortexed, centrifuged, and air-
dried for 10 minutes. Then the RNA-pellet is dissolved in 20 ul of RNase free 
water and concentration measured using a NanoDrop 1000 spectrophotometer. 
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Reverse Transcription of RNA to cDNA 
 1 ug of RNA and 2 ul of random decamers added to 0.2 ml propylene PCR 
8-tubes with clear caps (USA Scientific 1402-1900), and RNase-free water added 
to a volume of 10 ul. Samples are then heated to 80o C for 3 minutes on thermal 
cycler (MWG AG Biotech Primus 96 Plus). Next, 2 ul of 10X PCR buffer, 4 ul of 
dNTP mix, 1 ul of anti-RNase, and 1 ul of Reverse Transcriptase added to a final 
volume of 20 ul. Samples incubated on thermal cycler for 44o C for 1 hour, 
followed by incubation of 92o C for 10 minutes to inactivate reverse transcriptase.  
 
Analysis of mRNA Expression Using Quantitative Polymerase Chain 
Reaction (qPCR) 
 Reaction components for qPCR is mixed as follows: 0.5 ul template of 
cDNA, 12.5 ul SYBR Green PCR Master Mix (Agilent Technologies 410024), and 
7 ul distilled water. Reaction tubes were Mx4000 8-tube strips and caps (Agilent 
Technologies 410022 and 410024). From here, 5 ul primer mixture was added (3 
ul forward and 3 ul reverse added to 94 ul of RNase-free water) to each tube. 
Primers for human-myc-Rheb, Beta-galactosidase, ATGL, Egr1, Parkin, and p62. 
The exact nucleotide sequence for each of these primers is located in Table 3 
below. All samples were prepared in triplicate and mRNA expression levels were 
normalized to reference gene Ribosomal protein, large, P0 (RPLP0), also known 
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as, 36B4. Reactions were run at 95o C for 2 minutes followed by 30 cycles of 95o 
C for 2 minutes, 58o C for 30 seconds, 72o C for 1 minute, and 1 cycle of 72o C 
for 5 minutes. Reactions performed by Stratagene Mx4000 Mulitplex Quantitative 
PCR System and corresponding software Mx4000 version 4.20. 
Table 3. Primers used for RT-qPCR experiments. 
Primer Forward (5’ – 3’) Reverse (5’ – 3’) 
Human-myc-
Rheb 
CTATCGGCATGTGGGAAA
GT 
ATATTCATCCTGCCCTGCT
G 
Beta-
galactosidase 
ACGGTCTTCCCACTGAAC
AC 
CAGTATCGGCCGAGGTTA
AA 
ATGL TATCCGGTGGATGAAAGA
GC 
CAGTTCCACCTGCTCAGA
CA 
Egr1 CCACAACAACAGGGAGAC
CT 
ACTGAGTGGCGAAGGCTT
TA 
Parkin GGAAAGCTCCGAGTTCAG
TG 
CCTTGTCTGAGGTTGGGT
GT 
p62 CCCAGTGTCTTGGCATTC
TT 
GACTCAGCTGTAGGGCAA
GG 
 
 
qPCR Data Analysis and Statistics 
 As mentioned before, all qPCR data was prepared in triplicate and mRNA 
levels were normalized to ribosomal protein 36B4 in 3T3-L1 and murine 
adipocytes. Target mRNA set equal to 1.0 in a non-stimulated environment used 
as a baseline, and expression of target mRNA was calculated as a fold-increase 
in comparison to this baseline. Again, stimulatory environments included 
doxcyline for in vivo studies and insulin for in vitro studies.  
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Beta-Galactosidase Assay 
 
 Dissect AT depots from subcutaneous, epididymal, and mesenteric tissue 
and place into PBS containing 2 mM MgCl2 on ice. Fix in 0.5% glutaraldehyde in 
PBS and Mg2+ or 2.0% - 4.0% paraformaldehyde in PBS and Mg2+ on ice for 1 
hour. Rinse in many changes of PBS. Dilute the X-gal stock into X-gal Reaction 
Buffer and incubate with this tissue for 2-4 hours at 37o C. The X-gal Reaction 
Buffer contains 35 mM potassium ferrocyanide, 35 mM potassium ferricyanide, 2 
mM MgCl2, 0.02% Nonidet P-40, and 0.01% Sodium deoxycholate in PBS. Rinse 
many times in PBS until the solution no longer turns yellow. Lastly, view under 
bright field optics for optimal detection.  
  
Leptin Enzyme-linked Immunosorbent Assay (ELISA) 
 
 Leptin ELISA samples performed in duplicate for optimal results. Into two 
wells, add 100 ul of dilution buffer to blank the other samples, and then into wells 
B through H in rows 1 and 2, add 100 ul of Standards A through G. Into wells 
A3/A4, add 100 ul of a diluted control mouse serum. Next, add serum samples 
into wells, diluted at 1:2 or 1:5 with the dilution buffer. Cover the wells with 
sealing tape and incubate the plate for 1 hour at room temperature at 350 rpm. 
After incubation, aspirate the contents of the wells into a disinfectant and wash 
the wells 3 times with 300 ul of Washing Buffer, allowing incubation for at least 
15 seconds. Next, pipette 100 ul of the diluted Antibody Conjugate solution into 
each well, cover the wells with sealing tape and incubate for 30 minutes at room 
temperature, shaking at 350 rpm. After the incubation, wash again 3 times with 
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Washing Buffer. Pipette 100 ul of the diluted enzyme conjugate solution into each 
well, cover wells with sealing tape and incubate for another 30 minutes at room 
temperature and shake at 350 rpm. Wash wells again with washing buffer. 
Pipette 100 ul of the TMB-substrate solution S in each well and incubate the 
plate for 30 minutes at room temperature in the dark. Stop the reaction by adding 
100 ul of Stopping Solution in each well. Measure the absorbance within 15 
minutes at 450 nm using a colorimetric microplate reader (ELISA reader). Using 
the standards, determine the Leptin concentration.  
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RESULTS 
 
 In response to Chakrabarti et al. discovering the role of Egr1 in 
downregulation of ATGL expression, we have been directed toward studying the 
mechanism by which ATGL degradation occurs. This led us to research Parkin 
and p62. Parkin functions as an E3 ubiquitin ligase, involved in degradation of 
proteins. The other protein, p62, is a protein that recognizes ubiquitinated cargo 
and is then scavenged by a sequestration process known as autophagy. We 
could research all of these proteins through RT-qPCR. Using murine 3T3-L1 
adipocytes, cells were stimulated with 100 nm of insulin for different time periods. 
All qPCR reactions were performed in triplicate, and mRNA levels were 
normalized to 36B4 mRNA. This expression change was statistically significant 
(p<0.01) as assessed by the student’s t test (Figures 9 – 12). 
 As mTORC1 emerges as a central mediator of metabolic effects of insulin, 
we sought to study its role in vivo. To study the role of mTORC1 in nutrient intake 
and storage, we developed a doxycycline-inducible fat-specific constitutively 
active (ca) Rheb-transgenic mice. This will closely resemble physiological 
activation of mTORC1 by insulin. To create these mice, we were kindly provided 
with mice expressing rtTA specifically in adipocytes by Dr. Philipp Scherer. This 
Tet-responsive element in concert with doxycycline, will bind the promoter region 
of myc-Rheb, inducing its expression. A gene for beta galactosidase is present, 
located on the opposite DNA strand of human myc-Rheb, providing another 
mechanism to measure induction. 
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The generation of five double transgenic mouse lines was developed and 
three were lost during breeding procedures. The remaining two lines are UTBart 
and UTAaron, both in a C57BL/6 background. To confirm the presence of myc-
Rheb we used the primer located in Table 2, which amplified a region of 
nucleotides that was 450 base pairs (BP). To confirm the presence of rtTA, we 
used the primer sequence located in Table 2, which amplified a region of 
nucleotides that was 200 BP. An ethidium bromide gel was used to image and 
show that these mice expressed both myc-Rheb and rtTA shown in Figure 13. In 
this image, all but lane 5 showed mice that were double positive for these 
proteins, resulting in experimentation upon eight of nine mice. Rheb protein 
induction was studied through feeding doxycycline to mice of the UTAaron and 
UTBart line. Mice were put on a doxycycline diet for one week and then 
dissected for samples of liver, and subcutaneous, epididymal or parametrial, and 
mesenteric AT depots. The 3 depots were tested for Rheb and Beta-
galactosidase expression through qPCR and results are shown in Figures 14 and 
15 below. These mRNA expression changes were statistically significant 
(p<0.05) as assessed by the student’s t-test. Again, all qPCR reactions were 
performed in triplicate and normalized to the ribosomal protein 36B4. 
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Figure 9. ATGL expression in response to insulin. On day 8 OF 3T3-L1 
adipocyte differentiation, cells were serum-starved for 3 hours and then 
stimulated with 100 ul of insulin for different time periods. mRNA levels were 
normalized to 36B4,  a ribosomal protein. ATGL – adipose triglyceride lipase Ins 
– insulin 
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Figure 10. Egr1 expression in response to insulin. On day 8 OF 3T3-L1 
adipocyte differentiation, cells were serum-starved for 3 hours and then 
stimulated with 100 nm of insulin for different time periods. mRNA levels were 
normalized to 36B4,  a ribosomal protein. Egr1 – Early growth response factor 1 
Ins – insulin 
 
 
Figure 11. p62 expression in response to insulin. On day 8 OF 3T3-L1 
adipocyte differentiation, cells were serum-starved for 3 hours and then 
stimulated with 100 nm of insulin for different time periods. mRNA levels were 
normalized to 36B4,  a ribosomal protein. Ins – insulin 
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Figure 12. Parkin expression in response to insulin. On day 8 OF 3T3-L1 
adipocyte differentiation, cells were serum-starved for 3 hours and then 
stimulated with 100 nm of insulin for different time periods. mRNA levels were 
normalized to 36B4,  a ribosomal protein. Ins – insulin 
 
 
 
Figure 13. Genotyping Results of UTAaron mice. The top gel is primed for 
protein rtTA, a protein that is roughly 200 BP. The second gel below is primed for 
Rheb, a protein that is roughly 500 BP. rtTA – reverse tetracycline activator Rheb 
– Ras homolog enriched in brain BP – base pairs 
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Figure 14. Induction of Rheb and BGal in UTBart AT Depots. After a week of 
doxcylcine diet (red) and normal diet (blue), induction of Rheb and Beta 
Galactosidase was measured using RT-qPCR. AT samples were taken from 
three depots of tissue – subcutaneous, parametrial, and mesenteric. Rheb – Ras 
Homolog Enrich in Brain BGal – Beta Galactosidase P – Parametrial M – 
Mesenteric Q – Subcutaneous AT – Adipose Tissue cc – control mouse (DOB: 
10/17/13) cd – doxycycline fed mouse (DOB: 10/17/13) ce – doxcylcine fed 
mouse (DOB: 11/29/13) 
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Figure 15. Induction of Rheb and BGal in UTAaron AT Depots. After a week 
of doxcylcine diet (red) and normal diet (blue), induction of Rheb and Beta 
Galactosidase was measured using RT-qPCR. AT samples were taken from 
three depots of tissue – subcutaneous, parametrial, and mesenteric. Rheb – Ras 
Homolog Enrich in Brain BGal – Beta Galactosidase P – Parametrial M – 
Mesenteric Q – Subcutaneous AT – Adipose Tissue 1M – male doxcyline fed 
(DOB: Jul. 2013)  mouse 5M – male doxcylcine fed mouse (DOB: Nov. 2013) 2F 
– female doxcyline fed mouse (DOB: Jul. 2013) 7F – female doxycycline fed 
mouse (DOB: Nov. 2013) 
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DISCUSSION 
 
 As a result of the discovery by Chakrabarti et al that Egr1 is instrumental 
in the downregulation of ATGL, our lab sought to understand this pathway more 
fluently. Since ATGL is the rate-limiting enzyme in lipolysis and is not inhibited in 
the insulin-stimulated state in diabetics, we chose to study the factors that 
degrade this enzyme. It is understood that an activated mTORC1 increases the 
expression of Egr1 mRNA and protein. Egr1 binds the promoter region of ATGL, 
resulting in decreased transcription of this lipolytic enzyme. This antilipolytic 
signal is defective in T2DM and obesity, and as a result, these patients suffer 
from lipotoxic consequences.   
 The two proteins studied for ATGL degradation are Parkin and p62. 
Parkin, a protein encoded by the PARK2 gene, is a component of the E3 
ubiquitin ligase complex, responsible for targeting proteins for degradation. The 
other protein, p62, is responsible for recognizing toxic cellular waste and is then 
scavenged for autophagy. By using qPCR, we were able to assess changes in 
ATGL, Egr1, Parkin, and p62 mRNA in 3T3-L1 adipocytes upon stimulation by 
insulin, as shown by Figures 9 through 12.  
 In Figure 9 and 10, we again confirm the fact that Egr1 downregulates 
ATGL transcription and that it is upregulated by insulin in the mTORC1 axis. We 
confirm this finding through the use of qPCR and normalize the mRNA levels to 
ribosomal protein 36B4. Furthermore, Figure 10 shows that Egr1 mRNA increase 
precedes ATGL mRNA and protein decrease by hours. Our target of interest, 
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parkin, did not show data that related to ATGL degradation. We expect parkin 
levels to increase similarly with ATGL levels, though this was not the case. This 
was the same trend with p62 data, which showed no correlation similar with 
ATGL levels upon 100 ul insulin stimulation.  
 In our next set of experiments, we were set to breed double transgenic 
mice that we positive for myc-Rheb and rtTA. Our Rheb gene was tagged with 
myc and specific for AT. Figure 13 shows the genotyping process, where mice 
were checked for both genes and we continually bred until mice that were only 
homozygous for Rheb and rtTA were generated. In Figure 13, the mouse in lane 
4 was positive for rtTA but not for Rheb, so it was null in experimentation. After 
developing these mice, 8 UTAaron mice were chosen for experimentation, 4 that 
were born in July of 2013 and the other 4 that were born in November 2013. Half 
of the mice were on a regular diet and the other half were on a doxycycline diet 
for one week prior to dissection. Again, mRNA levels were quantified through 
qPCR and normalized to ribosomal protein 36B4. The UTBart mice AT depots 
were responsive and it seems that Rheb and Beta Galactosidase genes were 
induced through doxycycline feeding. In this strain of mice, mesenteric adipose 
depots showed the greatest induction followed by subcutaneous and lastly, 
parametrial depots. The UTAaron strain of mice induction was a bit more 
sporadic. Though we did not see induction in some depots, we did notice 
induction more often than not. Specifically, subcutaneous adipose depots 
showed the largest and most consistent induction. Although we are uncertain of 
	   43	  
UTAaron induction, UTBart mice show induction in all depots and should be used 
for further experimentation.  
 Now, through feeding doxycycline, we are able to induce Rheb and 
through this avenue, are now able to hyperactivate mTOR through insulin 
stimulation. This will lead to larger levels of Egr1 and lower levels of ATGL. Of 
course, by limiting this rate-limiting lipolytic enzyme, we may be able to avoid 
lipotoxicity and all of the negative associated consequences. 
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